Update on the pharmacological prevention of skeletal-related events in cancer patients

Orthopedics

Volumn 34, Issue 12, 2011, Pages 982-985

  Kennedy, Kenneth ^a   Patel, Hetalkumari ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG EFFECT; DRUG MECHANISM; FATIGUE; FLU LIKE SYNDROME; FRACTURE TREATMENT; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; JAW OSTEONECROSIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATHOLOGIC FRACTURE; PREVENTIVE HEALTH SERVICE; PROSTATE CANCER; RECOMMENDED DRUG DOSE; SIDE EFFECT; SPINAL CORD COMPRESSION; SPINE SURGERY; TUMOR MICROENVIRONMENT; VITAMIN SUPPLEMENTATION; VOMITING;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; MULTIPLE MYELOMA; PRESCRIPTION FEES; RANK LIGAND;

EID: 83655165338     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20111021-21     Document Type: Article

References (14)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2(8):584-593. (Pubitemid 37328925)
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-1664.
3. Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities [published online ahead of print January 4, 2011]. Nat Rev Endocrinol. 2011; 7(4):208-218.
4. Green J, Clézardin P. The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol. 2010; 37(suppl 1):S3-S11.
5. Bottiglieri S, Adams V, Smith KM. Pharmacologic prevention of skeletal-related events in cancer patients. Orthopedics. 2010; 33(8):577-580. doi: 10.3928/01477447-20100625-20.
6. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001; 7(5):377-387. (Pubitemid 33759002)
7. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases [published online ahead of print October 10, 2011]. Ann Oncol. In press.
8. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients [published online ahead of print August 1, 2006]. Br J Haematol. 2006; 134(6):620-623. (Pubitemid 44253605)
9. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer [published online ahead of print February 22, 2011]. J Clin Oncol. 2011; 29(9):1221-1227.
10. Percival RC, Urwin GH, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol. 1987; 13(1):41-49. (Pubitemid 17040425)
11. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study [published online ahead of print November 8, 2010]. J Clin Oncol. 2010; 28(35):5132-5139.
12. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study [published online ahead of print February 25, 2011]. Lancet. 2011; 377(9768):813-822.
13. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma [published online ahead of print February 22, 2011]. J Clin Oncol. 2011; 29(9):1125-1132.
14. Xgeva (denosumab) [package insert]. Thousand Oaks, CA: Amgen Inc; 2010.